A Phase II Study of Amrubicin as a Third-Line or Fourth-Line Chemotherapy for Patients With Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901

Amrubicin, a third-generation synthetic anthracycline agent, has favorable clinical activity and acceptable toxicity for the treatment of patients with non-small cell lung cancer (NSCLC) and small cell lung cancer. We conducted this study to evaluate the efficacy and safety of amrubicin for advanced...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Harada, Toshiyuki, Oizumi, Satoshi, Ito, Kenichiro, Takamura, Kei, Kikuchi, Eiki, Kuda, Tomoya, Sugawara, Shunichi, Suzuki, Aya, Maemondo, Makoto, Fujita, Yuka, Kinoshita, Ichiro, Inoue, Akira, Hommura, Fumihiro, Katsuura, Yutaka, Dosaka-Akita, Hirotoshi, Isobe, Hiroshi, Nishimura, Masaharu
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2013
Assuntos:
Lung Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3639531/
https://ncbi.nlm.nih.gov/pubmed/23442308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0308
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados